
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology
IMNN-101 induced 2- to 4-fold increase in neutralizing antibody (NAb) titers from baseline through Week 4
IMNN-101 continues to show an acceptable safety profile
LAWRENCEVILLE, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced new safety and immunogenicity data from ongoing analyses of results from the Company's first Phase 1 proof-of-concept clinical trial of IMNN-101, its investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine® technology platform. The Phase 1 study was conducted in 24 healthy volunteers as a seasonal COVID-19 vaccine, targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen. IMNN-101 was administered as a single dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Results demonstrated that IMNN-101 is safe and well-tolerated with no serious adverse effects. IMNN-101 induced a persistent 2- to 4-fold increase in serum neutralizing antibody (NAb) titers from baseline through Week 4, further increasing NAb titers between Week 2 and Week 4. The immune response was observed against the XBB1.5 variant and many newer variants following treatment, demonstrating the IMNN-101 vaccine's cross-reactivity.
'We have strong evidence of vaccine immunogenicity based on the neutralizing antibody response against the Omicron XBB.1.5 strain in this trial, and expect partnering interest in our proof-of-concept data from the PlaCCine platform,' said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. 'These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing vaccine candidates for protecting the population against a potential future exposure to a pathogen or controlling a rising pathogen. Given proof of immunogenicity, early indications of durability of protection, and competitive advantages in the stability of our vaccine at workable temperatures compared with available mRNA vaccines, we believe that IMNN-101 has significant potential as a superior next-generation vaccine and will seek potential partners for further development.'
The participants in the Phase 1 trial had high baseline immune characteristics presumably from prior infection and multiple previous vaccinations against COVID-19 and ongoing infection as evidenced by the rise in viral nucleocapsid antigen during the study period. Modest increases in T cell responses were observed in this setting of trial participants having received multiple immunizations prior to the study.
'Data from this trial is of high quality and show that IMUNON's DNA vaccine is immunogenic in humans. Following immunization, participants' NAb titers increased through Week 4 with a 2- to 4-fold increase from baseline, a clear and convincing response to the vaccination,' said Ai-ris Collier, M.D., Co-Director of the Clinical Trials Unit, Center for Virology and Vaccine Research Center, Beth Israel Deaconess Medical Center.
The Phase 1 clinical data of IMNN-101 is consistent with strong evidence of immunogenicity and protection for the PlaCCine platform in rodents and non-human primates, with prior preclinical results showing that protection exceeded 95% in non-human primates, which is comparable to mRNA vaccines. The robust immunogenicity profile, expected durability of protection, comparative ease of manufacturing, and stability at workable temperatures (up to one year at 4°C and one month at 37°C) suggest that our vaccine based on the PlaCCine technology platform may be a potential viable alternative to available messenger RNA (mRNA) vaccines.
About PlaCCine® and IMNN-101
IMNN-101 utilizes the company's PlaCCine® technology platform, a proprietary composition of a DNA plasmid that regulates the expression of key pathogen antigens and a novel synthetic DNA delivery system. The plasmid-based expression vector accommodates single or multiple antigens through its flexible vector design, offers manufacturing flexibility compared to with viral or other DNA or protein vaccines, and the synthetic delivery system protects DNA from degradation and facilitates DNA uptake after injection with acceptable safety.
About the Phase 1 PoC Clinical Trial
This U.S. Phase 1 proof-of-concept (PoC) study inoculated 24 participants to evaluate three escalating doses of IMNN-101 with eight participants at each dose. All participants were treated at DM Clinical Research in Philadelphia. For this study, IMNN-101 has been designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, in accordance with the FDA's Vaccines and Related Biological Products Advisory Committee's June 2023 announcement of the framework for updated COVID-19 doses. The primary objectives of the study are to evaluate safety and tolerability in healthy adults. Secondary objectives include evaluating IMNN-101's ability to elicit neutralizing antibody responses, cellular responses and their associated durability.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the delivery of DNA-coded viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing for commencement and potential outcome of a Phase 3 trial of IMNN-001, the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, the potential partnering opportunities, and the Company's plans and expectatio
ns with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
24 minutes ago
- CNN
Kennedy names new members of CDC vaccine advisory panel days after removing previous advisers
Just two days after retiring the entirety of the US Centers for Disease Control and Prevention's vaccine advisory panel, US Health and Human Services Secretary Robert F. Kennedy Jr. has appointed several prominent critics of the government's Covid-19 response to that committee. He announced eight new members of the CDC's Advisory Committee on Immunization Practices, or ACIP, on Wednesday. Kennedy had said Monday that the previous 17-member panel that makes recommendations on who should get vaccines and when was rife with conflicts of interest and that he would appoint new 'highly credentialed' experts in time for the panel's June 25 meeting, at which the members are expected to discuss guidance for Covid-19 and HPV shots, among others. In a statement Wednesday, Kennedy said the reassembled panel will demand 'definitive safety and efficacy data before making any new vaccine recommendations, but will also review data for the current vaccine schedule as well.' The eight new ACIP members include Dr. Robert Malone, a biochemist who made early innovations in the field of messenger RNA but in more recent years has been a vocal critic of mRNA technology in Covid-19 vaccines. The CDC recently narrowed its recommendations for mRNA Covid-19 shots, but some advocates in the Make America Healthy Again space have pressed Kennedy to go further and bar the vaccines entirely. Another new member is Dr. Martin Kulldorff, a biostatistician and epidemiologist who co-authored an October 2020 strategy on herd immunity known as the Great Barrington Declaration with Dr. Jay Bhattacharya, now director of the US National Institutes of Health. Both Malone's and Kulldorff's names were circulated early in the second Trump administration as potential advisers on ACIP or other panels, according to a person familiar with the process who requested anonymity because they weren't authorized to speak with CNN. Kennedy also chose Dr. James Pagano, an emergency medicine physician he described as a 'strong advocate for evidence-based medicine' who has served on hospital committees and medical executive boards. Dr. Retsef Levi, an MIT professor who has published studies on mRNA vaccines and cardiovascular events, is also joining the panel. Levi is a professor of operations management. Several of the new members have served in federal health agencies previously, including Dr. Joseph Hibbeln, a former acting chief of the NIH's section on nutritional neurosciences. Dr. Cody Meissner, a Dartmouth professor of pediatrics who also signed the Great Barrington Declaration, has previously served on ACIP and on the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee. Dr. Vicky Pebsworth, the Pacific region director of the National Association of Catholic Nurses, also served on the FDA committee and on a national panel reviewing the 2009 H1N1 swine flu vaccine. Dr. Michael Ross, a professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University, has previously served on the CDC's Advisory Committee for the Prevention of Breast and Cervical Cancer. Kennedy also nodded in his statement to Ross' 'continued service on biotech and healthcare boards.' The private equity company Havencrest, in which Ross is an operating partner, describes him on its site as a 'serial CEO' who has served on the boards of several biotechnology companies.
Yahoo
26 minutes ago
- Yahoo
Home Depot Targeted in Los Angeles Immigration Raids
The Home Depot, Inc. (NYSE:HD) is one of the best Dow stocks to invest in. Recently, the company has become a focal point in the recent federal immigration raids and the protests that followed in Los Angeles. On June 6, federal agents targeted a Home Depot in the Westlake area, along with other sites like Ambiance Apparel in downtown L.A., resulting in dozens of arrests. The arrests near The Home Depot, Inc. (NYSE:HD) involved day laborers hired by the store's customers, such as homeowners and contractors who often rely on undocumented workers for home repairs and construction. A The Home Depot, Inc. (NYSE:HD) spokesperson confirmed that the company was not informed about the raids beforehand and was not involved in the enforcement actions. The Atlanta-based retailer now faces challenges as its stores have become common targets for raids, which may discourage customers. On June 9, Home Depot's shares fell 0.6%, closing at $36.20. While we acknowledge the potential of HD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
26 minutes ago
- Yahoo
Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030
SAN MATEO, Calif., June 11, 2025--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the "Notes"). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025. The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually and will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option at par, plus a "make whole" premium, if applicable. The Company expects to use the net proceeds from this offering to repay outstanding secured indebtedness under the Company's existing financing arrangements. Goldman Sachs & Co. LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers of this offering. MUFG Securities Americas Inc., Zions Direct, Inc., RBC Capital Markets, LLC, Synovus Securities, Inc. and Keefe, Bruyette & Woods, A Stifel Company are acting as co-managers. The offering may be made only by means of a preliminary prospectus supplement and an accompanying prospectus. Copies of the preliminary prospectus supplement may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, or email: Prospectus-ny@ or telephone: 1-866-471-2526, or SMBC Nikko Securities America, Inc., 277 Park Avenue, New York, New York 10172, Attention: Debt Capital Markets – Transaction Management, or email: prospectus@ or telephone: 1-212-224-5135. Investors are advised to carefully consider the investment objectives, risks, charges and expenses of the Company before investing. The pricing term sheet dated June 11, 2025, the preliminary prospectus supplement dated June 11, 2025, and the accompanying prospectus dated December 11, 2024, each of which has been filed with the SEC, contain this and other information about the Company and should be read carefully before investing. The information in the pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may be changed. The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release do not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Hercules Capital, Inc. Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $22 billion to over 680 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact info@ or call (650) 289-3060. Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the "Adviser Subsidiary"), also maintains an asset management business through which it manages investments for external parties ("Adviser Funds"). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940. Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY). Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We may use words such as "anticipates," "believes," "expects," "intends," "will," "should," "may" and similar expressions to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and should not be relied upon in making any investment decision. Such statements are based on currently available operating, financial and competitive information and are subject to various risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. While we cannot identify all such risks and uncertainties, we urge you to read the risks discussed in our Annual Report on Form 10-K and other materials that we publicly file with the Securities and Exchange Commission. Any forward-looking statements made in this press release are made only as of the date hereof. Hercules assumes no obligation to update any such statements in the future. View source version on Contacts Michael HaraInvestor Relations and Corporate CommunicationsHercules Capital, Inc.(650) 433-5578mhara@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data